Search research articles
Contact Us
Filters
Showing results (141-150 of 155) with videos related to
Page
of 16
Sort By:
Journal of Medicinal Chemistry
|
August 16, 2011
Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose
Emmanuel H Demont, Sandra Arpino, Rino A Bit, et al.
Physical Review. E
|
May 14, 2016
Plasma scale-length effects on electron energy spectra in high-irradiance laser plasmas
O Culfa, G J Tallents, A K Rossall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate
Emmanuel H Demont, Benjamin I Andrews, Rino A Bit, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses
Emmanuel H Demont, James M Bailey, Rino A Bit, et al.
Journal of Medicinal Chemistry
|
July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Physical Review Letters
|
October 4, 2012
Controlling fast-electron-beam divergence using two laser pulses
R H H Scott, C Beaucourt, H-P Schlenvoigt, et al.
British Journal of Cancer
|
August 14, 2014
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
B P Schneider, L Li, F Shen, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 155) with videos related to
Sort By:
Page
of 16
Journal of Medicinal Chemistry
|
August 16, 2011
Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose
Emmanuel H Demont, Sandra Arpino, Rino A Bit, et al.
Physical Review. E
|
May 14, 2016
Plasma scale-length effects on electron energy spectra in high-irradiance laser plasmas
O Culfa, G J Tallents, A K Rossall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate
Emmanuel H Demont, Benjamin I Andrews, Rino A Bit, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses
Emmanuel H Demont, James M Bailey, Rino A Bit, et al.
Journal of Medicinal Chemistry
|
July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Physical Review Letters
|
October 4, 2012
Controlling fast-electron-beam divergence using two laser pulses
R H H Scott, C Beaucourt, H-P Schlenvoigt, et al.
British Journal of Cancer
|
August 14, 2014
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
B P Schneider, L Li, F Shen, et al.
Page
of 16